These mutations are more prevalent in cases involving strong familial BC history, younger patients, those with triple-negative breast cancer (TNBC) indicating the absence of HER2, estrogen, and progesterone receptors, and specific ethnic groups, such as Ashkenazi Jews who exhibit BRCA gene founder mutations. This evidence concerns the gene ERBB2 and breast cancer.